BioCentury | Oct 4, 2019

Selectivity sets off $37M series A for mTOR company Aeovian

Preclinical selectivity data for Aeovian’s mTORC1 inhibitor prompted venBio and Sofinnova Investments to co-lead the biotech’s $37 million series A after long eyeing the space. “mTORC1 selective inhibition has been a Holy Grail target in...
Items per page:
1 - 1 of 1